论文部分内容阅读
目的 :了解培菲康制剂中粪链球菌对于免疫抑制小鼠的致病力。方法 :用培菲康制剂中粪链球菌与由肺部感染病人的痰中分离的粪链球菌各 1株 ,分别在乳鼠组、免疫抑制乳鼠组、免疫抑制幼龄鼠组、免疫抑制成年鼠组、免疫抑制衰老鼠组、裸鼠组和免疫抑制裸鼠组等 7个组进行灌胃与腹腔注射 ,菌量为2 .0× 10 6CFU/次。结果 :给培菲康粪链球菌的各组中均无小鼠死亡 ,而给从病人痰中分离的粪链球菌的各组中均无小鼠死亡 ,而给从病人痰中分离的粪链球菌的免疫抑制成年小鼠组与免疫抑制衰老小鼠组各有 1只小鼠死亡 (均为腹腔注射后 ) ,其死亡率分别为 10 %与 16 .7%。结论 :培菲康制剂中粪链球菌在免疫抑制机体中未发现有致病力。
OBJECTIVE: To understand the virulence of Streptococcus faecalis in immunosuppressed mice. Methods: One strain of Streptococcus faecalis isolated from Pefiikang and one isolated from sputum of patients with pulmonary infection were divided into three groups: one in neonatal rats, one in immunosuppressed neonatal rats, one in immunosuppressed young rats, Adult mice, immunosuppressed mice, nude mice and immunosuppressed mice were randomly divided into 7 groups: intraperitoneal injection and intraperitoneal injection of 2 × 10 6 CFU per mouse. Results: None of the mice in the group of Pefiikang faecalis died of the disease, and none of the mice in each group of Streptococcus faecalis isolated from the patient’s sputum died of the feces from the patient’s sputum One of the cocci immunosuppressed adult mice and the immunosuppressed aged mice each died (both after intraperitoneal injection), with a mortality of 10% and 16.7%, respectively. CONCLUSION: Streptococcus faecalis is not found to be virulent in the immunosuppressed organisms.